Cwm LLC Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cwm LLC raised its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 201.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,072 shares of the biotechnology company’s stock after purchasing an additional 11,414 shares during the quarter. Cwm LLC’s holdings in BioCryst Pharmaceuticals were worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in BCRX. Deerfield Management Company L.P. Series C raised its holdings in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after buying an additional 3,140,804 shares during the period. Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after buying an additional 2,371,401 shares during the period. Kynam Capital Management LP boosted its position in shares of BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after buying an additional 1,927,491 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of BioCryst Pharmaceuticals by 528.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock valued at $6,874,000 after buying an additional 935,132 shares during the last quarter. Finally, Point72 Europe London LLP purchased a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth approximately $1,654,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays increased their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 6th. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Stock Up 1.5 %

Shares of BCRX opened at $8.18 on Friday. The firm’s fifty day moving average is $7.82 and its two-hundred day moving average is $6.76. The stock has a market cap of $1.69 billion, a PE ratio of -7.64 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. The firm’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.24) EPS. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.